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Abstract: Levocetirizine is the pharmacologically active enantiomer of cetirizine. It is a potent 
histamine H-1 receptor antagonist with anti-inﬂ  ammatory and antiallergic properties. The review 
analyses the levocetirizine’s properties in terms of safety and efﬁ  cacy both in allergic rhinitis 
and urticarioid syndromes.
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Levocetirizine (R-cetirizine), or (R)-[2-[4-[(4-chlorophenyl)phenylmethyl]-
1-piperazinyl]ethoxy]acetic acid dihydrochloride is the pharmacologically active 
enantiomer of cetirizine, and is a potent histamine H-1 receptor antagonist.1 Cetirizine 
consists of a racemic mixture of R- and S-cetirizine. The two enantiomers differ 
as to pharmacological activity, bond afﬁ  nity to the H-1 receptor, and dissociation 
constant. Various studies agree in attributing all pharmacological activity, higher bond 
afﬁ  nity, and longer dissociation half-life to R-cetirizine.2 These characteristics make 
levocetirizine an excellent pseudo-irreversible antagonist of the H-1 receptor, and one 
that is not as easily displaced by histamine as cetirizine on the H-1 receptor in vivo. 
The high power and speciﬁ  city of levocetirizine as inverse agonist for the H1 receptor3 
have been demonstrated both at the level of endothelial cells and of smooth muscle 
ﬁ  brocells of blood microcirculation.4 On these sites the antagonism of histamine is 
responsible for the inhibition of the increase in vascular permeability and vasodilation. 
Inhibition of edema formation and mucus secretion represent the result of levocetitizine 
effects on skin and respiratory mucosa, respectively. These pharmacological actions 
underlie the therapeutic effect of levocetirizine in urticaria and rhinitis.
Levocetirizine also has several other pharmacological effects partially related 
to its antagonism on the H-1. T lymphocytes, dendritic cells and lung macrophages 
express the histamine H-1 receptor on their cell surface which induces the expression 
of activation molecules and the synthesis of cytokines and chemokines with 
proinﬂ  ammatory effects when activated.5 Triggiani and colleagues have recently 
demonstrated that levocetirizine can inhibit the synthesis of IL-6 from human lung 
macrophages and histamine-induced production of IL-8 by dendritic cells.6
The inhibiting effects of levocetirizine have also been studied on keratinocytes, 
where it blocks the secretion of chemokines and GM-CSF.7 Additionally, recent 
studies have shown that levocetirizine reduces the expression of activation molecules 
(CD134 and ICAM-1) and of a transcription factor involved in the differentiation of 
Th2 lymphocytes (GATA-3).8
The inhibition of the NF-κB transcription factor complex induced by levocetiri-
zine suppresses the endothelial production of eotaxin, IL-1β, TNF-α and VCAM-1 
stimulated by histamine.9Journal of Asthma and Allergy 2009:2 18
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Lastly, levocetirizine signiﬁ  cantly inhibits both eotaxin-
induced eosinophil transendothelial migration10 and endothe-
lial adhesion,11 and modulates the release (at a concentration 
of 1 nM) of proinﬂ  ammatory cytokines such as IL-1β and 
IL-7 by liposaccharide-activated eosinophils, at the same 
time increasing the tissue inhibitors of metalloproteinase-1 
and -4 and of matrix metalloproteinase-9.12
The latter anti-inﬂ  ammatory and antiallergic properties 
are expressions of other pharmacological activities of 
levocetirizine9 not strictly correlated to its receptor antagonist 
action. Levocetirizine has been shown to have these properties 
at plasma concentrations between 10 and 500 nM,9,10 which 
is the range comprising the molecule’s plasma concentration 
(∼ 400 nM) during a standard treatment at a dose of 5 mg.13 
Other second generation antihistamines showed the same 
effects that were present only in vitro and at pharmacological 
concentrations unattainable in vivo.14
An innovative concept, which has emerged from the latest 
studies on levocetirizine, is that there may be a positive interac-
tion between the anti-inﬂ  ammatory effects and H-1 receptor 
antagonism. This hypothesis is based on the observation that 
H-1 is a highly dynamic receptor, whose expression on anti-
inﬂ  ammatory cells may be rapidly modulated (increased or 
inhibited). Recent data indicate that some cytokines (TNF-α, 
IL-8, IL-13) or growth factors (GM-CSF) can enhance the 
H-1 receptor’s expression on monocytes, macrophages and 
dendritic cells.15,16 By inhibiting the production of the cytokines 
and growth factors mentioned above, as well as the recruit-
ment of the cells involved in allergic immunophlogosis, the 
pharmacological blockage of H-1 and H-2 cell receptors by 
levocetirizine might modify the pathogenesis and clinical evo-
lution of allergic diseases.16 If veriﬁ  ed in vivo, this hypothesis 
could provide the basis for an effective synergy between anti-
inﬂ  ammatory action and H-1 receptor antagonism.
Safety of use of levocetirizine
The pharmacokinetics of levocetirizine present a linear 
correlation with the administered dose, are not time 
dependent, and exhibit little variability among different 
subjects. Administered orally, levocetirizine is absorbed 
quickly and broadly; its bonding to plasma proteins is 95% 
and its distribution volume is low (0.3 l/kg), which, for a H-1 
receptor antagonist, represents a real advantage.17 Because 
its metabolism is limited, its pharmacokinetics are poorly 
modiﬁ  ed by concomitant intake of other drugs. It is mainly 
excreted through the urine by glomerular ﬁ  ltration and active 
tubular secretion; therefore, it is recommended to prolong the 
time between doses in patients with chronic renal failure.
In regards to its safety proﬁ  le, no negative effects on 
alertness, reaction abilities, or ability to drive vehicles have 
emerged from the clinical studies reported in the literature 
after one or more doses of levocetirizine at the recommended 
dosage of 5 mg/day.18–22 Verster and colleagues18 have 
evaluated the effects of treatment with various antihistamines 
on memory, psychomotor abilities and mood state. Two 
antihistamines were examined: levocetirizine (5 mg) and 
diphenhydramine (50 mg) vs placebo, administered at three 
different times once daily on four consecutive days. The 
study group consisting of 48 healthy volunteers (24 males 
and 24 females) underwent a series of laboratory tests (verbal 
learning test, Sternberg memory test, pursuit test, divided 
attention test) three hours after the ﬁ  rst dose (acute phase) and 
at the end of the study, ie, on the fourth day (chronic phase). 
The results demonstrated that a single dose or repeated doses 
of levocetirizine had no modiﬁ  cation on memory, attention 
and motor skills, whereas diphenhydramine induced a 
signiﬁ  cant reduction in attention and motor skills as early 
as after the ﬁ  rst dose.18
In the same group, an assessment of the effects on driving 
skills showed not statistically signiﬁ  cant changes in the group 
treated with levocetirizine compared with placebo, unlike the 
results observed with diphenhydramine.19
The absence of sedative effects has been conﬁ  rmed 
by two other double-blind, placebo controlled clinical 
studies conducted to evaluate the effects on cognitive 
and psychomotor functions, in groups of 20 and 19 
subjects respectively, of treatment with levocetirizine20,21 
or ﬁ  rst-generation antihistamines like promethazine20 and 
diphenhydramine21 and second-generation antihistamines 
(cetirizine and loratadine).20
A study by Potter22 reports the absence of signiﬁ  cant adverse 
reactions during a six-week treatment with levocetirizine at 
5 mg/day. In both two examined groups (in treatment with 
levocetirizine and placebo) was reported at least one adverse 
reaction in similar percentages: 60.0%  and 68.1%, respectively.22 
The most frequent adverse reaction was headache (34.7% both 
for levocetirizine and for placebo), inﬂ  uenza-like symptoms 
(16.7% and 13.9%, respectively), high respiratory tract infec-
tions (6.7% and 9.0%, respectively) and drowsiness (6.0% and 
2.8%, respectively).22 Apart from the cases of drowsiness, no 
reduction of the memory and psychomotor functions has been 
demonstrated.20 In one subject there was an increase in alanine 
aminotransferase, correlated with the drug, which regressed 
spontaneously after nine days.22 During this study there were no 
cases of increased electrocardiogram (ECG) QT interval.22 The 
absence of cardiotoxic effects of levocetirizine has been recently Journal of Asthma and Allergy 2009:2 19
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conﬁ  rmed by a study conducted on 52 healthy subjects treated 
with 5 mg and 30 mg under dynamic monitoring according to 
Holter method in the 24 hours following the dose.23
A study conducted in Germany on 17,638 subjects (24) 
conﬁ  rmed the good tolerability of levocetirizine with a rate of 
1.6% of mild or moderate adverse reactions reported during 
administration (fatigue, headache, gastrointestinal disorders, 
dizziness, dry mouth). These adverse events compromised 
the subjects’ well being to a modest extent.
Efﬁ  cacy of levocetirizine
in allergic rhinitis
Allergic rhinitis is a high-prevalence chronic respiratory 
disease with a negative impact on the subjects’ quality of 
life, work activities, productivity or school performance, as 
well as on healthcare costs. Because of its benign nature, the 
importance of this condition is often underestimated.
Levocetirizine is an antihistamine molecule that has been 
shown by various studies to have an effective and immediate 
action in reducing eye and nose symptoms of seasonal as 
well as perennial rhinitis. Its efﬁ  cacy proﬁ  le in the chronic 
treatment of rhinitic patients has been demonstrated to be 
better than other second generation antihistamines, including 
desloratadine and fexofenadine.
An initial two-week randomized double-blind 
placebo-controlled study on 470 patients subdivided 
into three groups treated with 2.5, 5, and 10 mg levoce-
tirizine, respectively, demonstrated that levocetirizine 
is effective in reducing the symptoms measured using 
the Total Four-Symptom Score: T4SS (nasal pruritus, 
ocular pruritus, rhinorrhea, and sneezing) in patients 
with seasonal rhinitis compared with placebo, and that 
the effect is dose-dependent.25 Based on this study, it has 
been concluded that the 5 mg/day dosage presented the 
best risk–beneﬁ  t ratio for the treatment of nose and eye 
symptoms in seasonal allergic rhinitis.25
These results have been conﬁ  rmed and extended in a 
multicenter, randomized, double-blind placebo-controlled 
study on 294 patients with perennial rhinitis.26 A scale with 
four values of increasing severity, from 0 to 3, was used 
to assess the ﬁ  ve symptoms (rhinorrhea, nasal pruritus, 
ocular pruritus, sneezing, nasal congestion).26 Out of 294 
randomized patients, 144 were treated with placebo and 
150 with levocetirizine at dosages of 5 mg/day for six 
weeks. Improvements in T4SS vs placebo were 86% in 
the ﬁ  rst week and 47% at the end of the study.26 This study 
has also highlighted a signiﬁ  cant effect of levocetirizine on 
improvement of nasal congestion, one of the most annoying 
among the symptoms associated with rhinitis and generally 
poorly responsive to antihistamine treatment.26
The efficacy of 5 mg levocetirizine has been com-
pared with that of 10 mg loratadine in dust mites allergic 
patients by performing a challenge test in the Vienna 
Challenge Chamber, a special facility where patients are 
exposed to pre-determined amounts of allergen, allowing 
an accurate evaluation of drug effects on the symptoms that 
appear after the allergen exposure.27 In the double-blind, 
placebo-controlled cross-over study, 39 patients received 
the challenge test through a six-hour exposure to dust 
mite allergens on two consecutive days.27 The drugs were 
administered after two hours of exposure. Symptom severity 
was assessed using the Complex Symptom Score (CSS), 
consisting of the sum of the individual scores for rhinorrhea, 
nasal pruritus and sneezing.27 The percentage of patients with 
a CSS reduction of at least 20% was 43% for the placebo 
group, 66.7% for loratadine, 83.8% for levocetirizine, and the 
clinical improvement was achieved within 60 minutes after 
receiving levocetirizine, vs 90 minutes for loratadine.27
A comparative study vs desloratadine (the active 
enantiomer of loratadine), conducted on 23 subjects, also 
conﬁ  rmed the substantially higher rapidity of levocetirizine’s 
pharmacological action after a single dose administration.28 
In addition, levocetirizine showed a more protective effect, 
when compared to desloratadine, in patients with seasonal 
rhinitis submitted to the speciﬁ  c nasal challenge test.29
The effect of levocetirizine on nasal obstruction, 
compared to desloratadine, has also been recently conﬁ  rmed 
by Ciprandi and colleagues30 in a pilot study conducted on 
30 subjects with seasonal allergic rhinitis. The enrolled 
patients were assigned to randomized treatment with 
levocetirizine, desloratadine or placebo for two weeks 
and then assessed using a modiﬁ  ed TSS, including nasal 
congestion, as well as rhinomanometry to determine the 
presence of inﬂ  ammatory inﬁ  ltrate and cytokine secretion in 
the nasal secrete. The results have shown that only levocetiri-
zine, and not desloratadine, is able to improve nasal air ﬂ  ows 
and to reduce signiﬁ  cantly the IL-4 and IL-8 production.30
A comparison of the beginning and duration of the 
pharmacological action and clinical efﬁ  cacy of levocetirizine 
vs desloratadine had been previously conducted in another 
randomized, double-blind, parallel-group clinical study based 
on the model known as Environmental Exposure Unit (EEU), 
a special chamber that allows simultaneous exposure of up 
to 160 people at a predetermined level of pollen granules.31 
Out of 373 randomized patients, 141 were assigned to the 
cetirizine group, 140 to the desloratadine group, and 92 to the Journal of Asthma and Allergy 2009:2 20
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placebo group. The patients were exposed to Ambrosia pol-
len in the EEU for seven hours on Day 1 and for six hours 
on Day 2; the symptoms were measured every 30 minutes. 
Levocetirizine was found to achieve a signiﬁ  cant symptom 
reduction as early as the ﬁ  rst hour, compared with three 
hours required for desloratadine to act; additionally, 24 hours 
after the ﬁ  rst dose and just before receiving the second dose, 
symptom reduction was signiﬁ  cantly higher in the patients 
treated with levocetirizine compared to subjects that assumed 
desloratadine. Both active treatment groups showed symptom 
improvement compared to the placebo-group.31
In a comparative study vs fexofenadine at a dosage 
of 120 mg, levocetirizine at a dosage of 5 mg proved to have 
a more potent and long lasting action in reducing rhinitic 
symptoms 22–28 hours after the dose. Levocetirizine’s speed 
of action and clinical efﬁ  cacy resulted in a higher degree of 
patient satisfaction with the treatment.32
Another study compared levocetirizine’s efﬁ  cacy against 
fexofenadine in reducing nasal congestion symptoms.33 
The assessment was performed using infrared facial 
thermography, a noninvasive technique for the measurement 
of temperature changes in the nasal region. Because 
vasodilation and allergic immunophlogosis are associated 
with an increase in skin temperature in the nasal region, 
this technique allows the objective viewing of the patient’s 
clinical improvement in terms of reduced blood ﬂ  ow and 
nasal congestion.33 The double-blind, controlled, cross-over 
study assessed baseline thermography vs the value measured 
20 minutes after nasal challenge with histamine in 30 healthy 
subjects. The thermography was repeated in all 30 volunteers 
two hours and 24 hours after they had received 5 mg 
levocetirizine, 120 mg fexofenadine or placebo.33 While the 
thermography conﬁ  rmed the efﬁ  cacy of both antihistamine 
drugs in reducing immunophlogosis, as demonstrated by the 
signiﬁ  cant reduction in perinasal skin temperature compared 
with placebo two hours after administration, the measurement 
performed at 24 hours demonstrated that levocetirizine 
produces a more marked extension of the decongested nasal 
areas and a more prolonged nasal temperature reduction than 
fexofenadine.33
As suggested by the recent Allergic Rhinitis and its 
Impact on Asthma (ARIA) Guidelines,34 a new classiﬁ  cation 
of allergic rhinitis in intermittent or persistent form has 
been made according to symptom duration and severity. In 
persistent rhinitis the symptoms are present for more than 
four days a week and for more than four weeks a year.34
The results of XPERT (Xyzal in Persistent Rhinitis Trial), 
a 6-month multicenter, double-blind, placebo controlled study 
conducted on 551 patients with persistent allergic rhinitis, 
both perennial and seasonal, treated with levocetirizine 
and placebo confirmed that levocetirizine improves 
signiﬁ  cantly not only the clinical symptoms assessed by the 
TSS, but also the quality of life, as measured by the RQLQ 
(Rhinoconjuntivitis Quality of Life Questionnaire).35 After 
six months, levocetirizine improved the quality of life of 
allergic patients by more than 30% compared to placebo.35 
The study also demonstrated a reduction of the overall cost 
of the disease as calculated throughout the study period.35 
A more detailed analysis proved that levocetirizine helped 
achieve a 43% saving on the social cost of persistent 
allergic rhinitis, equal to approximately €153 per month 
per patient. In regards to employed patients, the saving was 
approximately €65 per month in terms of work days lost 
because of allergic rhinitis.36
Lastly, thanks to the widespread implementation of the 
ARIA guidelines34 and the recent scientiﬁ  c evidence of the 
role played by the H-1 receptor in allergic immunophlogosis,16 
levocetirizine might soon be added to the traditional therapies 
for the treatment of atopic bronchial asthma, as it has 
already demonstrated a protective effect against adenosine 
monophosphate-induced bronchospasm in 15 subjects with 
allergic asthma.37
Efﬁ  cacy of levocetirizine 
in urticarioid syndromes
Acute and chronic urticaria is one of the major diagnostic 
and therapeutic problem in allergologic ﬁ  eld. The etiological 
diagnosis of urticaria is not always possible, and in fact it 
is formulated in less than 50% of the cases; moreover, this 
condition is often a symptom of systemic diseases of various 
natures (infective, metabolic or neoplastic). Consequently, the 
treatment of these patients, especially of those with chronic 
idiopathic urticaria, is particularly complex, as the pathogene-
sis of this clinical variant includes self-immune mechanisms38 
with activation of tissue factors of coagulation.39,40
An initial study on 18 healthy volunteers was conducted 
on a model of allergic skin reaction after histamine prick 
test at a concentration of 100 mg/mL.41 The areas, expressed 
in mm2, of both the wheal and the surrounding ﬂ  are were 
calculated at different times after the test (0.5, 1, 2, 4, 6, 8, 
10, 12, and 24 hours). Levocetirizine demonstrated higher 
efﬁ  cacy and more prolonged action in inhibiting histamine-
induced wheal formation than ebastine (10 mg), fexofenadine 
(180 mg), mizolastine (10 mg), and loratadine (10 mg).41
A comparison with cetirizine also showed that a 
2.5 mg once daily oral dose of levocetirizine inhibited Journal of Asthma and Allergy 2009:2 21
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the histamine-induced wheal formation almost entirely 
in 18 normal subjects.42 The inhibiting effect was compa-
rable to that achieved with 5 mg of cetirizine. The effect of 
levocetirizine began after approximately one hour, reached 
its peak six hours after administration and persisted for 28 
hours.42
Subsequent studies conﬁ  rmed the blocking effect of 
levocetirizine on the histamine-induced skin reaction, 
and demonstrated its greater efficacy compared with 
desloratadine.28,43,44
Levocetirizine induces a quantitatively greater reduction 
of histamine wheal in a higher percentage of patients for a 
longer time than desloratadine.44
A recent investigation conducted on 18 allergic patients 
submitted to aeroallergen skin prick tests (SPT) measured 
the surface, in mm2, of the SPT-induced wheal and ﬂ  are 
before and after the administration of placebo, desloratadine 
and levocetirizine.45 A serum and receptor assay of both 
antihistamine drugs was also performed. The study provided 
evidence that levocetirizine achieved stronger and more 
effective H-1 receptor blockage than desloratadine, although 
the latter was found in higher concentration at skin level.45
However, given the complexity of chronic idiopathic 
urticaria, the doubt remained whether levocetirizine would 
prove equally effective.
In an initial double-blind, placebo controlled study, 
levocetirizine–although at different dosages (2.5, 5, and 
10 mg)–produced a signiﬁ  cant improvement in clinical 
parameters (pruritus intensity and duration, wheal number 
and size) and quality of life score, as determined using the 
Dermatology Life Quality Index (DLQI)46 in 258 patients 
with chronic idiopathic urticaria. The therapeutic effect of 
levocetirizine was signiﬁ  cant when compared to placebo as 
early as the ﬁ  rst week of treatment, and persisted throughout 
the entire duration of the study (4 weeks) even at the 
minimum dosage of 2.5 mg.46
Subsequent studies have conﬁ  rmed levocetirizine’s 
speed of action and efﬁ  cacy in 166 patients with chronic 
urticaria.47 The objective was to measure the change 
induced by levocetirizine on itching severity one week 
and four weeks after treatment, according to a scale from 
0 (no itching) to 3 (more than 6 hours of itching per day), 
and to evaluate the quality of life through the DLQI.47 
During the ﬁ  rst week, treatment with 5 mg levocetirizine 
led to a marked improvement of itching severity and a 
reduction in wheal number and size compared with pla-
cebo. These effects remained stable throughout the three 
following weeks.47
During treatment, the quality of life (DLQI) score 
improved in both groups, but more noticeably in the group 
treated with levocetirizine.47 The results of the study on 
treatment impact on cost and productivity parameters are 
also noteworthy. The number of drug intakes because of 
a new ﬂ  are-up of urticaria was considerably lower in the 
levocetirizine group than in the placebo group (approximately 
10 times lower: 2.5 vs 25.9). Patients treated with 
levocetirizine also improved their work productivity during 
the study period.47
In a six-week double-blind, placebo-controlled study we 
conducted, the efﬁ  cacy of levocetirizine was assessed in a 
population of 106 patients with chronic idiopathic urticaria 
at a daily dosage of 5 mg.48 The investigation included an 
assessment of symptoms (pruritus; number, size and spread 
of the wheal lesions; number of new ﬂ  are-ups, with scores 
of 0 to 3 according to severity) using TSS and VAS (Visual 
Analogue Scale at 10 cm); the assessment was then veriﬁ  ed 
through a 5-question survey on QoL changes.48 As early as 
the ﬁ  rst three weeks, the study conﬁ  rmed levocetirizine to be 
markedly more effective than placebo in reducing the scores 
of the considered scales (TSS, VAS, QoLQ).48 At the end of 
treatment 53% of the patients who had received levocetirizine 
reported total disappearance of symptoms, reduced itching 
intensity (85%), reduced number and spread of the wheal 
lesions (79% and 75% respectively) in signiﬁ  cant percentages 
compared to subjects treated with placebo. Moreover, the 
beneﬁ  cial effects of the treatment persisted up to seven days 
after the treatment suspension.48
An analysis of costs in 294 patients with chronic idiopathic 
urticaria treated with levocetirizine vs placebo has recently 
conﬁ  rmed that, in terms of work and social costs, levocetiri-
zine allows monthly savings for €91.93 per individual patient 
on the costs of medical investigations, combined therapies, 
days of hospital stays and loss of work productivity resulting 
in treatment costs of more than €1 per day.49
Conclusions
Levocetirizine is a newly developed selective H-1 antagonist 
and is the R-enantiomer or active isomer of the racemate ceti-
rizine. Its small volume of distribution, smaller even than that 
of cetirizine, confers improved safety because of its lesser pas-
sage through the blood-brain barrier and low cerebral receptor 
binding. The drug’s safety is conﬁ  rmed by the absence of 
cardiotoxic effects and the mild nature of the reported adverse 
reactions (fatigue, headache, dizziness, and dry mouth) during 
treatment, which do not generally interfere with the patient’s 
well being even in the case of chronic treatment.Journal of Asthma and Allergy 2009:2 22
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According to the examined studies, levocetirizine 
represents a potent, consistent and long-lasting medication 
for the treatment of both intermittent and persistent allergic 
rhinitis and chronic idiopathic urticaria. In patients with 
allergic rhinitis, treatment with levocetirizine at a dose of 
5 mg daily produced a signiﬁ  cant decrease in sneezing, 
rhinorrhea, itching nose, itching eyes and nasal congestion. 
Also the efﬁ  cacy of levocetirizine to treat chronic idiopathic 
urticaria was widely demonstrated. In particular, a long-term 
treatment with this antihistamine can improve the quality of 
life and symptoms and decrease the overall costs of allergic 
diseases; these are some of the key criteria for the successful 
treatment of chronic diseases.
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